Niraparib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Niraparib

Examples of brand names: Zejula [EU/DE]

ATC code: L01XK02

Main use (for orientation): Selected cancers

Documented research summary

Synergy with a cannabis fraction / THC–CBC–CBG mixture in ovarian cancer models; not established for individual cannabinoids in humans.

Uncertainties and limitations

Single-ingredient oral product for human use in the US SPL; no claim regarding German brand availability or authorisation.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

THC/CBC/CBG mixture or cannabis fractions – laboratory and animal studies

Finding ID: B0185

Type of result: Preclinical evidence

Observation: THC-rich F5/F7 fractions or standard mixtures were synergistic with niraparib; the strongest cannabinoid mixture was THC+CBC+CBG.

Mechanism: PARP1/Wnt signalling pathway

Study type: Cell / ex-vivo experiment

Context studied: HTB75/HTB161 ovarian cancer cells and patient-derived cells ex vivo; no evidence for an individual cannabinoid.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: Abstract read, no patient pharmacokinetic data; no dosage or treatment recommendation.

Original sources for this finding: Phytocannabinoid Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. [BMED36364346]

Cannabis fraction F7 – laboratory and animal studies

Finding ID: B0186

Type of result: Preclinical evidence

Observation: The combination caused cell-cycle arrest / ER stress, reduced migration and the number of ALDH-positive cells, and increased PARP1 cleavage.

Mechanism: Hippo/Wnt, TGF-β, MAPK, PARP1 cleavage

Study type: Cell / ex-vivo experiment

Context studied: Caov3/OVCAR3; follow-up study by the same research group, not independent clinical evidence.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: Abstract read, no patient pharmacokinetic data; no dosage or treatment recommendation.

Original sources for this finding: Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment. [BMED38322025]

References and access status

[V2_LABEL_D0393] ZEJULA (NIRAPARIB) TABLET, FILM COATED [GLAXOSMITHKLINE LLC]

Original source / bibliographic reference

Authors: GlaxoSmithKline LLC

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED36364346] Phytocannabinoid Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian Cancer Cells In Vitro and Affect the Wnt Signaling Pathway.

Original source / bibliographic reference

Authors: Shalev N, Kendall M, Anil SM, Tiwari S, Peeri H, Kumar N, Belausov E, Vinayaka AC, Koltai H.

Year: 2022

Source type: Publication; title and abstract reviewed

DOI: 10.3390/molecules27217523

PMID: 36364346

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED38322025] Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment.

Original source / bibliographic reference

Authors: Shalev N, Kendall M, Kumar N, Tiwari S, Anil SM, Hauschner H, Swamy SG, Doron-Faingenboim A, Belausov E, Kendall BE, Koltai H.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.3389/fgene.2024.1333964

PMID: 38322025

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility